Calvin Pan, MD
Gastroenterology · Flushing, NYNPI 1427062108
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $432,844 of the $608,811 with a category attached, or 71.1%. 28 manufacturers reported payments, led by Gilead at 47.8% of the total. Reporting peaked in 2019 at $210,598 and has fallen 96.1% since, to $8,112 in 2025. Among gastroenterology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 875 payments — averaging $695.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$291K
- AbbVie$172K
- Nestle Healthcare Nutrition Inc.$66K
- Intercept Pharmaceuticals, Inc.$48K
- Shionogi Inc$9K
- GSK$7K
- plus $15K from 22 others
Across 44 payments — averaging $1718.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$76K
What the payments were for
- Consulting fees$133,23522%
- Speaking & faculty fees$432,84471%
- Travel & lodging$19,8333%
- Food & beverage$22,8844%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 325 | $291,008 |
| AbbVie(2 entities) | 230 | $171,572 |
| Nestle Healthcare Nutrition Inc. | 95 | $66,499 |
| Intercept Pharmaceuticals, Inc. | 50 | $48,189 |
| Shionogi Inc | 14 | $9,168 |
| GSK | 4 | $6,892 |
| Ironwood Pharmaceuticals, Inc | 9 | $5,776 |
| Intra-sana Laboratories | 13 | $3,421 |
| Siemens Medical Solutions USA, Inc. | 4 | $2,397 |
| Eisai Inc. | 2 | $1,370 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 40 | $633 |
| Ardelyx, Inc. | 24 | $481 |
| Vivus LLC | 20 | $387 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $343 |
| Bristol Myers Squibb | 6 | $134 |
| Ipsen Biopharmaceuticals, Inc | 1 | $104 |
| Phathom Pharmaceuticals, Inc. | 3 | $67 |
| Braintree Laboratories, Inc. | 3 | $48 |
| Madrigal Pharmaceuticals | 2 | $46 |
| QOL Medical, LLC | 2 | $45 |
| Echosens North America, Inc. | 2 | $44 |
| Redhill Biopharma Inc. | 2 | $39 |
| Aimmune Therapeutics, Inc. | 2 | $38 |
| Celltrion USA Inc. | 1 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Exact Sciences | 1 | $22 |
| Orphalan Inc | 1 | $19 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$608,811 in reported general payments places this provider in the 95th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 91 | $165,037 |
| VemlidyTenofovir Alafenamide | 113 | $164,848 |
| LinzessLinaclotide | 108 | $58,105 |
| ZenpepLipase/Protease/Amylase | 18 | $28,255 |
| Mesalamine | 90 | $18,611 |
| OzempicSemaglutide | 11 | $10,467 |
| Sucralfate | 264 | $10,013 |
| Dexlansoprazole DrDexlansoprazole | 49 | $7,070 |
| Esomeprazole Magnesium | 172 | $2,970 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 41 | $2,470 |
| Ursodiol | 29 | $2,445 |
| Entecavir | 12 | $1,169 |
| Lubiprostone | 13 | $748 |
| Famotidine | 34 | $274 |
| Proctozone-HcHydrocortisone | 25 | $238 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $171,572 | $223,142199 claims |
| GileadVemlidy | $291,008 | $164,848113 claims |
| Aimmune Therapeutics, Inc.Zenpep | $38 | $28,25518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,682 gastroenterology providers in New York.
Other gastroenterology in Flushing
- Ari BunimFlushing$297K
- Stephen EspositoFlushing$190K
- David Carr LockeNew York$2M
- Arthur KornbluthNew York$1.9M
- Maya SrivastavaWilliamsville$1.8M
- Melissa PalmerPlainview$1M
- Sonal KumarNew York$1M
- David PoppersNew York$939K
- Ellen ScherlNew York$857K
- Bruce SandsNew York$810K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.